– USA, MA – Aegle Therapeutics, a clinical-stage dermatology-focused biopharmaceutical company developing novel therapies for those living with rare and severe skin diseases, announced the appointment of Dr. Scott Braunstein (M.D.) as Chairman of the Board of Directors, bringing over 30 years of knowledge and experience from diverse biotechnology and pharmaceutical industry vantage points.
About Dr. Scott Braunstein
Dr. Scott Braunstein served as President and CEO of Marinus Pharmaceuticals, Inc., a company focused on rare forms of epilepsy, until acquired by Immedica Pharma AB. Before that, he served as SVP, Strategy and COO at Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company. Before Pacira, Dr. Braunstein spent 12 years with J.P. Morgan Asset Management as a Managing Director, Healthcare Analyst, and the Portfolio Manager of the J.P. Morgan Global Healthcare Fund.
Dr. Braunstein has been an operating partner at Aisling Capital since 2015. He currently serves on the board of directors for atai Life Sciences N.V., Caribou Biosciences, Inc., RAPT Therapeutics, and Site One Therapeutics, a clinical-stage neurology company that is being acquired by Eli Lilly. Dr. Braunstein previously served on the board of directors of Trevena Inc., Esperion Therapeutics, Inc., Ziopharm Oncology Inc., Protara Therapeutics, Inc., and Constellation Pharmaceuticals, Inc.
Dr. Braunstein began his career as a practicing physician at the Summit Medical Group and as an Assistant Clinical Professor at Albert Einstein College of Medicine and Columbia University Medical Center. Dr. Braunstein received an M.D. from the Albert Einstein College of Medicine and a BASc in biology from Cornell University.
About Aegle Therapeutics Corporation
Aegle Therapeutics is a clinical-stage dermatology-focused biopharmaceutical company developing novel EV therapies to treat rare and severe dermatological disorders with significant unmet medical need. The company’s lead product candidate, AGLE-102, is currently in a phase 1/2a study for the treatment of recessive dystrophic epidermolysis bullosa and has completed a proof-of-concept study in severe burns. AGLE-102 has the potential to treat all subtypes of epidermolysis bullosa as well as a broad range of other dermatological indications characterized by inflammation resulting from an underlying immune imbalance.
For more information: https://aegletherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.